Re: 'Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis'
- PMID: 34099362
- DOI: 10.1016/j.ejca.2021.05.001
Re: 'Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis'
Conflict of interest statement
Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Comment in
-
Response to letter entitled: Re: Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis.Eur J Cancer. 2021 Jul;152:257-258. doi: 10.1016/j.ejca.2021.05.002. Epub 2021 Jun 8. Eur J Cancer. 2021. PMID: 34112565 No abstract available.
Comment on
-
Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis.Eur J Cancer. 2020 Sep;137:136-143. doi: 10.1016/j.ejca.2020.06.033. Epub 2020 Aug 4. Eur J Cancer. 2020. PMID: 32763784
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
